Bionano Genomics Inc (BNGO)

NASD · Healthcare · Medical Instruments & Supplies · USA

Bionano Genomics Inc is a micro cap company (market value under $300 million) in the Medical Instruments & Supplies industry.

Bionano Genomics provides genome analysis solutions including optical genome mapping systems that detect structural variations in chromosomes for research and clinical applications. The company offers nucleic acid extraction systems, diagnostic testing services through Bionano Laboratories, and software for genomic data interpretation. Its products serve researchers and clinicians in basic, translational, and clinical research.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Bionano Genomics Inc stock.

Our verdict on BNGO

Undervalued: intrinsic value $1.33 per share, market price $0.95, margin of safety 28.4% (as of 2026-11-17).

A 0.8x revenue multiple, discounted for its losses, values the shares at $1.33; the price of $0.95 is 28% below that value.

ETFs with the most weight in BNGO

More on BNGO

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than BNGO in Medical Instruments & Supplies

Is BNGO undervalued or overvalued?

BNGO is undervalued (as of the 2026-11-17 close). A 0.8x revenue multiple, discounted for its losses, values the shares at $1.33; the price of $0.95 is 28% below that value.

What is the intrinsic value of BNGO?

$1.33 per share (as of the 2026-11-17 close), against a market price of $0.95. That is a margin of safety of 28.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.